idera pharmaceuticals inc (IDRA) Key Developments
Idera Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 6 15
Idera Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenues were $5,000 against $38,000 a year ago. Loss from operations was $12,776,000 against $8,329,000 a year ago. Net loss applicable to common stockholders was $12,719,000 or $0.11 per basic and diluted share against $8,426,000 or $0.10 per basic and diluted share a year ago.
For the six months, revenues were $39,000 against $41,000 a year ago. Loss from operations was $25,299,000 against $17,302,000 a year ago. Net loss applicable to common stockholders was $25,200,000 or $0.23 per basic and diluted share against $17,572,000 or $0.22 per basic and diluted share a year ago.
Idera Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:05 PM
Jul 13 15
Idera Pharmaceuticals, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-11-2015 03:05 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States. Speakers: Louis J. Arcudi, Chief Financial Officer, Senior Vice President of Operations and Treasurer.
Idera Pharmaceuticals Appoints Mark J. Casey as General Counsel and Secretary of the Board of Directors
Jun 29 15
Idera Pharmaceuticals, Inc. has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors. Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated.
Idera Pharmaceuticals Enters into Strategic Clinical Research Alliance with The University of Texas MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination with Checkpoint Inhibitors
Jun 8 15
Idera Pharmaceuticals, Inc. announced that the company has entered into a strategic clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses. The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab (a CTLA4 antibody) in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, as well as to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of the year 2015. The trial will enroll approximately 45 patients. The company expects data to be available in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are currently in the planning stages.
Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM
May 27 15
Idera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 01:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer, President and Director.